Sporadic unilateral retinoblastoma or first sign of bilateral disease?

Temming, Petra; Viehmann, Anja; Biewald, Eva; Lohmann, Dietmar

doi:10.1136/bjophthalmol-2012-302666

Cited by 19 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sequential, contralateral eye involvement in our group of patients was always Group A disease, which was amenable to treatment with focal modalities without a significant loss of vision. Several authors have previously reported that approximately 20% of patients before 6 months of age with unilateral disease eventually became bilateral patients [2,16]. Abramson et al [2] recommended that this factor should be considered when making treatment decisions at diagnosis, but we found unconvincing evidence for this treatment concept in our series.…”

Section: Discussioncontrasting

confidence: 55%

Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age

Berry¹,

Jubran

Lee³

et al. 2015

Ocul Oncol Pathol

View full text Add to dashboard Cite

Aim: The purpose of this study was to evaluate the outcomes of infants diagnosed with retinoblastoma before 6 months of age, including the need for chemoreduction (CRD). In this age group, dosage of CRD was reduced due to its potential for toxicity. Methods: This is a retrospective review from 2000 to 2009 that includes 126 eyes of 72 infants (18 unilateral, 54 bilateral). Systemic CRD was administered when local modalities failed or were considered inadequate. Primary outcome measures were the need for CRD and globe salvage. Results: Of the 72 infants diagnosed before 6 months of age, 48 (67%) ultimately required CRD for globe salvage, 40 (56%) patients before 6 months of age. Globe salvage was achieved in 62% (78/126) of eyes overall and in 93% (68/73) of eyes with Group A-C disease. No patient was hospitalized for CRD-related illness; survival was 100%. The mean follow-up was 52.9 months (range 1-148 months). Conclusion: Utilizing a combination of focal modalities and reduced-dose CRD, children diagnosed with retinoblastoma before 6 months of age attain globe salvage rates comparable to those of older age groups. Two thirds of the infants ultimately required CRD for globe salvage. Bilateral disease as well as Group D and E classification in at least one eye at presentation increased the chance of requiring CRD (p < 0.0001 and p < 0.016, respectively).

show abstract

Section: Discussioncontrasting

confidence: 55%

Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age

Berry¹,

Jubran

Lee³

et al. 2015

Ocul Oncol Pathol

View full text Add to dashboard Cite

show abstract

“…They detected six low-level mosaic mutations in bilateral Rb and four in unilateral Rb, increasing their detection rate from 96% to 97% for bilateral Rb and from 13% to 18% for unilateral Rb. Since the detection of germline mosaicism has important clinical consequences for the patient and family members as has been pointed out in many papers,26 39 the ultimate goal remains to detect all RB1 mutations, both in the tumour and the germline.…”

Section: Discussionmentioning

confidence: 99%

RB1mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Messmer 40 quantified and found delays of ≥120 days to be statistically significant for the development of metastatic retinoblastoma. Patients presenting with glaucoma and/or buphthalmia have significantly elevated pathologic risk factors, including those resulting in microscopically residual disease and optic nerve invasion 33,41,42…”

Section: High Risks In Retinoblastomamentioning

confidence: 99%

Risk definition and management strategies in retinoblastoma: current perspectives

Ghassemi

Khodabande

2015

OPTH

View full text Add to dashboard Cite

This manuscript focuses on high-risk factors of metastatic disease in retinoblastoma and evaluation of the current treatments of retinoblastoma. Presence of histopathologic high-risk factors is associated with a higher risk of local recurrence and systemic metastasis. Currently, globe-sparing therapies, including systemic chemotherapy, intra-arterial chemoreduction, intravitreal chemotherapy, focal consolidation, and combination therapies, are being used and investigated actively. Major advances are being made in the diagnosis and management of retinoblastoma that will lead to improved morbidity and mortality rates in patients with retinoblastoma. By saving the globes, fronting with some high-risk factors for metastasis would be inevitable. International multi-institutional prospective studies could resolve current uncertainties regarding the main tumor treatment regimens for each patient and indications for chemoprophylaxis for high-risk-factor-bearing retinoblastoma cases.

show abstract

Sporadic unilateral retinoblastoma or first sign of bilateral disease?

Cited by 19 publications

References 11 publications

Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age

Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age

RB1mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients

Risk definition and management strategies in retinoblastoma: current perspectives

Contact Info

Product

Resources

About